The Readout Loud

→ WHAT IT COVERS This episode covers three biotech stories: Vinay Prasad's second departure from the FDA and its impact on rare disease drug approvals, Xenon Pharmaceuticals' phase three seizure trial results, the Novo Nordisk and Hims & Hers compounded GLP-1 settlement, and biotech investor Boris Nikolic's return to venture capital despite deep ties to Jeffrey Epstein.

→ WHAT IT COVERS The Readout Loud covers two major biotech stories: UniCure's regulatory standoff with the FDA over sham surgery requirements for its Huntington's disease gene therapy, and Spire Therapeutics CEO Cameron Turtle explaining how combination biologics aim to break IBD's 30% remission ceiling. → KEY INSIGHTS - **IBD Efficacy Ceiling:** Every approved IBD drug class — including biologics like Entyvio and Skyrizi — achieves clinical remission in only roughly 25–30% of patients.

→ WHAT IT COVERS Adam Feuerstein and Mizuho Securities analyst Jared Holtz assess biotech sector conditions in early 2026, covering the Gilead-Arcellx $7.9B acquisition, FDA regulatory inconsistencies affecting rare disease drugs, the widening Eli Lilly versus Novo Nordisk valuation gap, midterm election implications for drug pricing, and AI's potential disruption of the industry. → KEY INSIGHTS - **M&A Timing Strategy:** The Gilead-Arcellx deal at $7.

→ WHAT IT COVERS Three major healthcare stories dominate: the FDA's reversal on Moderna's flu vaccine application amid political pressure from the Trump administration, Compass Pathways reporting positive Phase 3 psychedelic depression trial results, and Hims & Hers facing FDA scrutiny, an HHS-DOJ referral, and a 30% stock drop after launching a compounded semaglutide pill.

→ WHAT IT COVERS The FDA refuses to review Moderna's mRNA flu vaccine application despite prior approval of trial design. Director Vinay Prasad overrules vaccine office staff, demanding high-dose comparator instead of standard-dose vaccine used in the 41,000-person trial that showed 27% greater effectiveness and 49% fewer hospitalizations. → KEY INSIGHTS - **Regulatory Precedent Reversal:** Moderna received written FDA approval in 2023 for using standard-dose flu vaccine as comparator in their...

→ WHAT IT COVERS This episode examines three major biotech developments: Novo Nordisk forecasts sales decline while Eli Lilly projects 23-27% growth in GLP-1 obesity drugs, Compass Pathways' psychedelic depression treatment gets removed from Trump's priority voucher program, and Vertex's CRISPR sickle cell therapy Kascevi faces severe manufacturing delays due to difficult stem cell collection.

→ WHAT IT COVERS Lipitor (atorvastatin) became history's most profitable drug, earning over $125 billion, by treating high cholesterol to prevent heart disease. The episode examines how Framingham Heart Study established cholesterol as a risk factor, how statins were discovered from Japanese mold research, and why aggressive marketing expanded prescriptions to 90 million Americans despite controversy over who truly benefits from treatment.

→ WHAT IT COVERS Patient advocate Lauren Holder discusses Huntington's disease and the FDA's reversal on UniCure's gene therapy, which showed 75% slowing of disease progression over three years. The agency initially accepted the trial design with external controls, then rejected it months later, devastating a community with twice the general population's suicide rate.

→ WHAT IT COVERS South Carolina faces a measles outbreak with 650 cases since October, potentially surpassing last year's West Texas outbreak as the largest in decades. The US may lose its measles elimination status after 25 years. Meanwhile, nonprofit hospital executives at JPM conference focus on financial stability amid projected Medicaid cuts exceeding one trillion dollars over the next decade.

→ WHAT IT COVERS STAT reporters interview Novo Nordisk CEO Mike Duster about obesity market competition and commercial strategy, followed by venture capitalist Bob Nelsen discussing FDA regulatory reform, China's biotech ascent, AI's impact on drug development, and intellectual property protection. Both guests address how pharmaceutical companies must adapt to accelerating technological change and global competition.

→ WHAT IT COVERS The Readout Loud examines big pharma's strengthened position entering 2026 after negotiating favorable drug pricing deals with the Trump administration. The episode previews the JPMorgan Healthcare Conference, analyzes merger and acquisition momentum including potential Revolution Medicines deals, and discusses FDA uncertainty under new leadership affecting biotech regulatory standards.

→ WHAT IT COVERS The Readout Loud reviews biotech's 2025 performance with venture capitalist Bruce Booth, covering market recovery data, CEO performance rankings, GLP-1 drug pricing dynamics, FDA stability concerns, and venture capital trends. Clinical stage biotechs gained 62% year-to-date while zombie biotech numbers declined significantly. → KEY INSIGHTS - **Biotech Market Recovery:** Clinical stage biotech companies surged 62% year-to-date, with the XBI index beating the S&P 500 by 200...

→ WHAT IT COVERS The Readout Loud examines disruptions to American biomedical research under the Trump administration, including NIH funding cuts and scientist layoffs. The episode also covers breakthrough data from the American Society of Hematology conference, featuring Terns Pharmaceuticals' chronic myeloid leukemia drug and new obesity treatments showing unprecedented weight loss with significant side effects.

→ WHAT IT COVERS Tracy Beth Hoag becomes FDA's new drug center leader after Rick Pazder's departure over concerns about commissioner Marty Makari's influence. David Olson discusses developing neuroplastogens—drugs that provide psychedelic therapeutic benefits without hallucinogenic effects—and Delix Therapeutics' phase one trial results showing rapid antidepressant effects comparable to traditional psychedelics.

→ WHAT IT COVERS Mark Cuban discusses his Cost Plus Drugs company's mission to disrupt pharmaceutical pricing through transparency and direct-to-consumer sales. He explains how PBMs control drug access through formulary leverage, why brand manufacturers avoid working with him, and announces biosimilar offerings like Stelara at drastically reduced prices compared to traditional channels.